武汉协和医院心血管病免疫研究跨越25年  

Cardiovascular immunology research in Wuhan Union Hospital:a 25 year experience spanning

作　　者：廖玉华[1] 王一逸 程翔[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院心内科、心血管病免疫实验室、教育部生物靶向治疗重点实验室,武汉430022

出　　处：《临床心血管病杂志》2017年第1期1-5,共5页Journal of Clinical Cardiology

基　　金：国家自然科学基金项目(No:39370317,30370574,31370931,81270331,91439207);国家科技部973项目(No:2007CB512000,2007CB512005)

摘　　要：武汉协和医院心血管病免疫学研究始于1991年,25年来通过大量的临床和实验研究,发现了抗L型钙通道抗体引起扩张型心肌病患者室性心动过速(室速)和猝死,证实了地尔硫能显著减少扩张型心肌病患者的死亡和心力衰竭(心衰)住院率,解释了心肌损伤后心衰的T细胞亚群失衡发病机制,提出了免疫调节治疗心衰的新策略,并最先发明了针对AT1受体的治疗性降压疫苗。未来仍有许多心血管病免疫学研究工作要完成。The cardiovascular immunology research in Wuhan Union Hospital originated in 1991 and lasted for 25 years.Through many clinical and experimental studies,a series of research achievements have been reported as follows.It was found that novel autoantibodies against L-type calcium channel result in ventricular tachycardia and sudden death in patients with dilated cardiomyopathy（DCM）.Diltiazem was verified to reduce mortality and chronic heart failure（CHF）hospitalization rate significantly in the treatment of DCM.The functional imbalance of T cell subsets was suggested to mediate myocardial injury and CHF,which provided a new theoretical basis for immunoregulation therapy of heart failure.The first antihypertensive ATRQβ-001 polypeptide vaccine was invented.In addition to these achievements,there will be more research on cardiovascular immunology in Wuhan Union Hospital in the future.

关 键 词：自身抗体 T细胞 高血压 扩张型心肌病 心力衰竭 疫苗 

分 类 号：R593[医药卫生—内科学]